Clinical trials: Obese Adults
Obesity
A Study to Learn About the Study Medicine Called PF-07976016 in Adults With Obesity
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07976016) for the potential treatment of obesity.
- Trial name
- NCT06717425
- Testing
- PF-07976016
- Where
- 38 sites in United States, Canada and 1 more
- Volunteers
- 263 people
- Sponsor
- Pfizer
Overweight , Obesity
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of IBIO-600 in Overweight or Obese Adults
The goal of this clinical trial is to learn which dose of study drug IBIO-600 has the right balance of safety, tolerability and impact on body composition in overweight and obese adult participants.
- Trial name
- NCT07487376
- Testing
- IBIO-600
- Where
- Australia
- Volunteers
- 32 people
- Sponsor
- iBio, Inc.
Obesity
Creation of Side-to-Side Compression Anastomosis Using the Magnetic Anastomosis System
This is an operationally seamless, open-label, multicenter study enrolling up to 50 subjects with obesity and with or without type 2 diabetes at up to 5 study centers across Canada and Europe who will undergo sleeve gastrectomy…
- Trial name
- NCT05322122
- Testing
- Side-to-side anastomosis duodeno-ileostomy diversion procedure
- Where
- 4 sites in Belgium, Canada and 2 more
- Volunteers
- 49 people
- Sponsor
- GT Metabolic Solutions, Inc.
Type 2 Diabetes, Obesity
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk.
- Conditions
- Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight
- Trial name
- ACHIEVE-4 (NCT05803421)
- Testing
- Orforglipron, Insulin Glargine
- Where
- 358 sites in United States, Argentina and 14 more
- Volunteers
- 2,749 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight and Obesity
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
The main purpose of this study, performed under a master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safety with Mazdutide compared with placebo and in adult participants with obesity or…
- Trial name
- NCT06124807
- Testing
- Mazdutide
- Where
- 29 sites in United States
- Volunteers
- 179 people
- Sponsor
- Eli Lilly and Company
Obesity &Amp; Overweight
Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Adults With Obesity or Overweight Without Diabetes Mellitus
This Phase 3 study is designed to evaluate the efficacy and safety of IN-B00009 injection in adults with obesity or overweight without diabetes mellitus
- Trial name
- NCT07192263
- Testing
- IN-B00009
- Volunteers
- 300 people
- Sponsor
- HK inno.N Corporation
Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic…
- Trial name
- NCT06836609
- Testing
- ALN-CIDEB
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 132 people
- Sponsor
- Regeneron Pharmaceuticals
Resting Metabolic Rate, Overweight Subjects
A Study to Investigate the Effect of 7-Keto on Resting Metabolic Rate in Overweight Adults
This study will investigate the effect of two different doses of 7-Keto compared to placebo on resting metabolic rate. One third of subjects will be given the lower 7-Keto dose, one third will be given the higher 7-Keto dose and…
- Trial name
- 15KMHI (NCT04782024)
- Testing
- 7-Keto 50mg, 7-Keto 25mg
- Where
- 2 sites in United States
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- KGK Science Inc.
Obesity
A Study to Assess S-309309 in Healthy and Obese Participants
The primary aim of the study is to assess the safety and tolerability of S-309309 after oral administration in healthy adult or obese but otherwise healthy adult participants.
- Trial name
- NCT05247970
- Testing
- S-309309, Midazolam
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Shionogi
Obesity
The Acute Effect of Grains of Paradise (Aframomum Melegueta) on REE
Grains of paradise (Aframomumu melegueta) (GP), also known as Guinea pepper or Alligator pepper, belongs to the Zingiberaceae family, which is native to West Africa.
- Trial name
- NCT03894137
- Testing
- Grains of Paradise (Aframomum Melegueta)
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Plexus Worldwide
Cardiovascular Risk Factor
A Pilot Study to Investigate the Effect of Water-soluble Tomato Extract on TMAO
To determine the effect of 4 weeks daily consumption of Fruitflow on changes in plasma levels of fasting Trimethylamine N-oxide concentrations (TMAO)
- Trial name
- NCT04160481
- Testing
- FruitFlow
- Where
- Ireland
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- dsm-firmenich Switzerland AG
Insulin Resistance
Safety, Pharmacokinetics and Potential Activity of HE3286 in Obese Adult Subjects
The objectives of this study are to evaluate the safety, tolerance and pharmacokinetics of HE3286 when administered daily for 28 days to obese adult subjects and to assess potential activity of HE3286 to decrease insulin…
- Trial name
- NCT00555451
- Testing
- HE3286
- Where
- 2 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Harbor Therapeutics
Overweight and Obesity
Assessment of the Safety, Tolerability, and Pharmacokinetic of GMA106
This will be a single centre, Phase 1, placebo-control, randomized, double-blind, sequential single and multiple ascending dose study to assess the safety, tolerability, and PK of GMA106 in healthy, overweight or obese subjects.
- Trial name
- NCT05054530
- Testing
- GMA106 Injection
- Where
- Australia
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- Gmax Biopharm Australia Pty Ltd.
Obesity, Overweight
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.
- Trial name
- SURMOUNT-MMO (NCT05556512)
- Testing
- Tirzepatide
- Where
- 671 sites in United States, Argentina and 26 more
- Volunteers
- 15,374 people
- Sponsor
- Eli Lilly and Company
Overweight or Obesity
A Phase III Study to Evaluate the Efficacy and Safety of MDR-001 in Adult Participants With Overweight or Obesity (MOBILE）
This is a multicenter, randomized, double-blind, placebo-controlled, phase III clinical study to evaluate the efficacy and safety of the oral small molecule MDR-001 Tablets over 52 weeks as an adjunct to a lifestyle intervention…
- Trial name
- NCT07274137
- Testing
- MDR-001
- Where
- 45 sites in China
- Volunteers
- 738 people
- Sponsor
- MindRank AI Ltd
Diabetes Mellitus and Heart Failure
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
This was a dose-finding study to evaluate the efficacy, safety and tolerability of 3 different doses of LIK066 compared to placebo or empagliflozin in T2DM patients with heart failure
- Trial name
- NCT03152552
- Testing
- LIK066, Empagliflozin
- Where
- 106 sites in United States, Argentina and 22 more
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals
Obese Adult Male
A Study of RTA 402 in Obese Adults
To investigate changes in body weight and body composition in obese adults after repeated oral administration of RTA 402 once daily for 16 weeks, using placebo as a control.
- Trial name
- NCT04018339
- Testing
- Bardoxolone methyl
- Where
- Japan
- Volunteers
- 22 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Obesity, Overweight
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of treatment with LY3549492 compared to placebo in adult participants with obesity or who are overweight…
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- NCT07030868
- Testing
- LY3549492
- Where
- 42 sites in United States, Argentina
- Volunteers
- 1 people
- Sponsor
- Eli Lilly and Company
Obesity, Overweight
THE ENLIGHTEN STUDY
The primary objective of this study is to demonstrate the safety and efficacy of the Elipse Gastric Balloon System for the treatment of obese adults.
- Trial name
- NCT03261453
- Testing
- Active Elipse Device
- Where
- 12 sites in United States
- Volunteers
- 400 people
- Sponsor
- Allurion Technologies
Bariatric Surgery, Obesity
Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery
The purpose of this study is to evaluate safety and efficacy of twice-daily ARD-101 in subjects at least one year after bariatric surgery (sleeve gastrectomy or gastric bypass).
- Conditions
- Bariatric Surgery, Obesity, Weight Gain
- Trial name
- NCT05215847
- Testing
- ARD-101
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Aardvark Therapeutics, Inc.